Kathryn E. Lafond
Centers for Disease Control and Prevention
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kathryn E. Lafond.
PLOS Medicine | 2016
Kathryn E. Lafond; Harish Nair; Mohammad Hafiz Rasooly; Fátima Valente; Robert Booy; Mahmudur Rahman; Paul Kitsutani; Hongjie Yu; Guiselle Guzmán; Daouda Coulibaly; Julio Armero; Daddi Jima; Stephen R. C. Howie; William Ampofo; Ricardo Mena; Mandeep S. Chadha; Ondri Dwi Sampurno; Gideon O. Emukule; Zuridin Nurmatov; Andrew Corwin; Jean-Michel Heraud; Daniel E. Noyola; Radu Cojocaru; Pagbajabyn Nymadawa; Amal Barakat; Adebayo Adedeji; Marta von Horoch; Remigio M. Olveda; Thierry Nyatanyi; Marietjie Venter
Background The global burden of pediatric severe respiratory illness is substantial, and influenza viruses contribute to this burden. Systematic surveillance and testing for influenza among hospitalized children has expanded globally over the past decade. However, only a fraction of the data has been used to estimate influenza burden. In this analysis, we use surveillance data to provide an estimate of influenza-associated hospitalizations among children worldwide. Methods and Findings We aggregated data from a systematic review (n = 108) and surveillance platforms (n = 37) to calculate a pooled estimate of the proportion of samples collected from children hospitalized with respiratory illnesses and positive for influenza by age group (<6 mo, <1 y, <2 y, <5 y, 5–17 y, and <18 y). We applied this proportion to global estimates of acute lower respiratory infection hospitalizations among children aged <1 y and <5 y, to obtain the number and per capita rate of influenza-associated hospitalizations by geographic region and socio-economic status. Influenza was associated with 10% (95% CI 8%–11%) of respiratory hospitalizations in children <18 y worldwide, ranging from 5% (95% CI 3%–7%) among children <6 mo to 16% (95% CI 14%–20%) among children 5–17 y. On average, we estimated that influenza results in approximately 374,000 (95% CI 264,000 to 539,000) hospitalizations in children <1 y—of which 228,000 (95% CI 150,000 to 344,000) occur in children <6 mo—and 870,000 (95% CI 610,000 to 1,237,000) hospitalizations in children <5 y annually. Influenza-associated hospitalization rates were more than three times higher in developing countries than in industrialized countries (150/100,000 children/year versus 48/100,000). However, differences in hospitalization practices between settings are an important limitation in interpreting these findings. Conclusions Influenza is an important contributor to respiratory hospitalizations among young children worldwide. Increasing influenza vaccination coverage among young children and pregnant women could reduce this burden and protect infants <6 mo.
The Journal of Infectious Diseases | 2012
Ndahwouh Talla Nzussouo; Jennifer Michalove; Ousmane M. Diop; Richard Njouom; Maria de Lourdes Monteiro; Herve Kadjo Adje; Serge Manoncourt; Joseph Amankwa; Lamine Koivogui; Samba O. Sow; Mohamed Brahim Elkory; Jean-Marc Collard; Ibrahim Dalhatu; Mbayame Ndiaye Niang; Kathryn E. Lafond; Filomena Moniz; Daouda Coulibaly; Karl C. Kronman; Buhari Oyofo; William Ampofo; Boubou Tamboura; Ahmed Ould Bara; Jean-François Jusot; Ekanem Ekanem; Fatoumata Diene Sarr; Inzune Hwang; Claire Cornelius; Babajide Coker; Stephen Lindstrom; Richard Davis
To understand 2009 pandemic influenza A virus subtype H1N1 (A[H1N1]pdm09) circulation in West Africa, we collected influenza surveillance data from ministries of health and influenza laboratories in 10 countries, including Cameroon, from 4 May 2009 through 3 April 2010. A total of 10,203 respiratory specimens were tested, of which 25% were positive for influenza virus. Until the end of December 2009, only 14% of all detected strains were A(H1N1)pdm09, but the frequency increased to 89% from January through 3 April 2010. Five West African countries did not report their first A(H1N1)pdm09 case until 6 months after the emergence of the pandemic in North America, in April 2009. The time from first detection of A(H1N1)pdm09 in a country to the time of A(H1N1)pdm09 predominance varied from 0 to 37 weeks. Seven countries did not report A(H1N1)pdm09 predominance until 2010. Introduction and transmission of A(H1N1)pdm09 were delayed in this region.
PLOS ONE | 2013
Mandeep S. Chadha; Siddhivinayak Hirve; Fatimah S. Dawood; Pallavi Lele; Avinash Deoshatwar; Somnath Sambhudas; Sanjay Juvekar; Kathryn E. Lafond; Joshua A. Mott; Renu B. Lal; Akhilesh C. Mishra
Background Influenza is vaccine-preventable; however, the burden of severe influenza in India remains unknown. We conducted a population-based study to estimate the incidence of laboratory confirmed influenza-associated hospitalizations in a rural community in western India. Methods We conducted active surveillance for hospitalized patients with acute medical illnesses or acute chronic disease exacerbations in Pune during pandemic and post pandemic periods (May 2009–April 2011). Nasal and throat swabs were tested for influenza viruses. A community health utilization survey estimated the proportion of residents hospitalized with respiratory illness at non-study facilities and was used to adjust incidence estimates from facility-based surveillance. Results Among 9,426 hospitalizations, 3,391 (36%) patients were enrolled; 665 of 3,179 (20.9%) tested positive for influenza. Of 665 influenza positives, 340 (51%) were pandemic A(H1N1)pdm09 and 327 (49%) were seasonal, including A/H3 (16%), A/H1 (3%) and influenza B (30%). The proportion of patients with influenza peaked during August 2009 (39%) and 2010 (42%). The adjusted annual incidence of influenza hospitalizations was 46.8/10,000 during pandemic and 40.5/10,000 during post-pandemic period with comparable incidence of A(H1N1)pdm09 during both periods (18.8 and 20.3, respectively). The incidence of both pH1N1 and seasonal hospitalized influenza disease was highest in the 5–29 year olds. Conclusions We document the previously unrecognized burden of influenza hospitalization in a rural community following the emergence of influenza A(H1N1)pdm09 viruses in India. During peak periods of influenza activity circulation i.e during the monsoon period, 20% of all hospital admissions in the community had influenza positivity. These findings can inform development of influenza prevention and control strategies in India.
The Journal of Infectious Diseases | 2015
Meredith McMorrow; Emile Okitolonda Wemakoy; Joelle Kabamba Tshilobo; Gideon O. Emukule; Joshua A. Mott; Henry Njuguna; Lilian W. Waiboci; Jean-Michel Heraud; Soatianana Rajatonirina; Norosoa Harline Razanajatovo; Moses Chilombe; Dean B. Everett; Robert S. Heyderman; Amal Barakat; Thierry Nyatanyi; Joseph Rukelibuga; Adam L. Cohen; Cheryl Cohen; Stefano Tempia; Juno Thomas; Marietjie Venter; Elibariki Mwakapeje; Marcelina Mponela; Julius J. Lutwama; Jazmin Duque; Kathryn E. Lafond; Ndahwouh Talla Nzussouo; Thelma Williams; Marc-Alain Widdowson
Abstract Background. Data on causes of death due to respiratory illness in Africa are limited. Methods. From January to April 2013, 28 African countries were invited to participate in a review of severe acute respiratory illness (SARI)–associated deaths identified from influenza surveillance during 2009–2012. Results. Twenty-three countries (82%) responded, 11 (48%) collect mortality data, and 8 provided data. Data were collected from 37 714 SARI cases, and 3091 (8.2%; range by country, 5.1%–25.9%) tested positive for influenza virus. There were 1073 deaths (2.8%; range by country, 0.1%–5.3%) reported, among which influenza virus was detected in 57 (5.3%). Case-fatality proportion (CFP) was higher among countries with systematic death reporting than among those with sporadic reporting. The influenza-associated CFP was 1.8% (57 of 3091), compared with 2.9% (1016 of 34 623) for influenza virus–negative cases (P < .001). Among 834 deaths (77.7%) tested for other respiratory pathogens, rhinovirus (107 [12.8%]), adenovirus (64 [6.0%]), respiratory syncytial virus (60 [5.6%]), and Streptococcus pneumoniae (57 [5.3%]) were most commonly identified. Among 1073 deaths, 402 (37.5%) involved people aged 0–4 years, 462 (43.1%) involved people aged 5–49 years, and 209 (19.5%) involved people aged ≥50 years. Conclusions. Few African countries systematically collect data on outcomes of people hospitalized with respiratory illness. Stronger surveillance for deaths due to respiratory illness may identify risk groups for targeted vaccine use and other prevention strategies.
Influenza and Other Respiratory Viruses | 2013
Vivek Gupta; Fatimah S. Dawood; Sanjay K. Rai; Shobha Broor; Rajan Wigh; Akhilesh C. Mishra; Kathryn E. Lafond; Joshua A. Mott; Marc-Alain Widdowson; Renu B. Lal; Anand Krishnan
Objective: Clinical case definitions used for influenza surveillance among hospitalized patients vary and need systematic evaluation.
The Lancet Global Health | 2016
John C. Victor; Kristen D.C. Lewis; Aldiouma Diallo; Mbayame Ndiaye Niang; Bou Diarra; Ndongo Dia; Justin R. Ortiz; Marc Alain Widdowson; Jodi Feser; Rebecca Hoagland; Shannon L. Emery; Kathryn E. Lafond; Kathleen M. Neuzil
Summary Background Live attenuated influenza vaccines have been shown to significantly reduce influenza in diverse populations of children, but no efficacy studies have been done in resource-poor tropical settings. In Senegal, we assessed the efficacy and safety of a live attenuated influenza vaccine based on Russian-derived master donor viruses and licensed as a single dose. Methods In this double-blind, placebo-controlled, parallel group, single-centre trial done near Niakhar, Senegal, generally healthy children aged 2–5 years were randomly allocated (2:1) to receive a single intranasal dose of masked trivalent live attenuated influenza vaccine or placebo. The allocation sequence was computer-generated by PATH with block sizes of three. The manufacturer provided vaccine and placebo in coded vials to preserve blinding. Participants were monitored through the predictable influenza season in Senegal for adverse events and signs and symptoms of influenza using weekly home visits and surveillance in clinics. The primary outcome was symptomatic laboratory-confirmed influenza caused by any strain and occurring from 15 days post-vaccination to the end of the study. The primary analysis was per protocol. This study is registered with ClinicalTrials.gov, number NCT01854632. Findings Between May 23, and July 1, 2013, 1761 children were randomly assigned, 1174 to receive live attenuated influenza vaccine and 587 to receive placebo. The per-protocol set included 1173 vaccinees and 584 placebo recipients followed up to Dec 20, 2013. Symptomatic influenza was laboratory-confirmed in 210 (18%) of 1173 recipients of live attenuated influenza vaccine and 105 (18%) of placebo recipients, giving a vaccine efficacy of 0·0% (95% CI −26·4 to 20·9). Adverse events were balanced between the study groups. Two girls who had received live attenuated influenza vaccine died, one due to anasarca 12 days postvaccination and one due to malnutrition 70 days postvaccination. Interpretation Live attenuated influenza vaccine was well tolerated in young children in Senegal, but did not provide protection against influenza. Further study in such populations, which might experience extended periods of influenza circulation, is warranted. Funding US Centers for Disease Control and Prevention and Bill & Melinda Gates Foundation.
Influenza and Other Respiratory Viruses | 2012
Justin R. Ortiz; Kathryn E. Lafond; Tiffany A. Wong; Timothy M. Uyeki
Please cite this paper as: Ortiz et al. (2012) Pandemic influenza in Africa, lessons learned from 1968: a systematic review of the literature. Influenza and Other Respiratory Viruses 6(1), 11–24.
Clinical Infectious Diseases | 2011
David Sugerman; Kelly H. Nadeau; Kathryn E. Lafond; Wendy Cameron; Karl Soetebier; Michael A. Jhung; Alexander Isakov; Ian Greenwald; Karen P. Neil; Stephanie J. Schrag; Alicia M. Fry
During August through September 2009, a surge in emergency department (ED) visits for 2009 pandemic influenza A (pH1N1) illness occurred in Georgia, particularly among children. To understand surge preparedness and capacity, we obtained influenza-like illness (ILI) ED visit data from the Georgia State Electronic Notifiable Disease Surveillance System (SendSS) and conducted a retrospective, Internet-based survey among all 26 metro Atlanta ED managers with reference to the period 1 July-1 October 2009. SendSS detected a marked and progressive increase in mean monthly ILI visits from 1 July-1 October 2009, which more than tripled (from 399 to 2196) for the 2 participating EDs that cared for pediatric patients during this time. ED managers reported patient volume surges, resulting in space and supply limitations, especially at pediatric EDs. Most (92%) of the facilities had current pandemic influenza plans. Pandemic planning can help to ensure preparedness for natural and man-made disasters and for future influenza pandemics.
Epidemiology and Infection | 2015
Aaron D. Storms; R. Kusriastuti; S. Misriyah; Catharina Y. Praptiningsih; M. Amalya; Kathryn E. Lafond; Gina Samaan; R. Triada; Angela D. Iuliano; M. Ester; R. Sidjabat; K. Chittenden; R. Vogel; Marc-Alain Widdowson; Frank Mahoney; Timothy M. Uyeki
Indonesia has reported the most human infections with highly pathogenic avian influenza (HPAI) A(H5N1) virus worldwide. We implemented enhanced surveillance in four outpatient clinics and six hospitals for HPAI H5N1 and seasonal influenza viruses in East Jakarta district to assess the public health impact of influenza in Indonesia. Epidemiological and clinical data were collected from outpatients with influenza-like illness (ILI) and hospitalized patients with severe acute respiratory infection (SARI); respiratory specimens were obtained for influenza testing by real-time reverse transcription-polymerase chain reaction. During October 2011-September 2012, 1131/3278 specimens from ILI cases (34·5%) and 276/1787 specimens from SARI cases (15·4%) tested positive for seasonal influenza viruses. The prevalence of influenza virus infections was highest during December-May and the proportion testing positive was 76% for ILI and 36% for SARI during their respective weeks of peak activity. No HPAI H5N1 virus infections were identified, including hundreds of ILI and SARI patients with recent poultry exposures, whereas seasonal influenza was an important contributor to acute respiratory disease in East Jakarta. Overall, 668 (47%) of influenza viruses were influenza B, 384 (27%) were A(H1N1)pdm09, and 359 (25%) were H3. While additional data over multiple years are needed, our findings suggest that seasonal influenza prevention efforts, including influenza vaccination, should target the months preceding the rainy season.
Vaccine | 2012
Wayne M. Sullender; Karen B. Fowler; Anand Krishnan; Vivek Gupta; Lawrence H. Moulton; Kathryn E. Lafond; Marc Alain Widdowson; Renu B. Lal; Shobha Broor
The burden of disease due to influenza is not well characterized for children in developing countries and the effectiveness of available influenza vaccines in lower resource settings has not been established. We initiated a prospective, longitudinal, phase IV, household-randomized, controlled, observer-blinded three year study (2009-2011) in a rural community of India to measure the total and indirect household protective effects of immunizing children ages 6 months through 10 years with seasonal inactivated trivalent influenza vaccine (TIV) or a control vaccine (n=3697). Active weekly surveillance was conducted year round with home visits for identification of febrile acute respiratory illness (FARI) conducted for all vaccine recipients and household members (n=18,220). Nasal and throat swabs were collected from each FARI episode for influenza detection by real-time reverse transcription polymerase chain reaction. The primary outcome was reduction in laboratory confirmed influenza infections in the influenza vaccine versus control vaccine group, with secondary outcome assessing indirect effects among the entire study population. This report describes the study site, cluster study design, choice of study and control vaccines, and the initial enrollment in the study.